SC
ARQT icon

Stempoint Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Stempoint Capital’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-825,000
Closed -$516K – 47
2024
Q1 		$516K Buy
+825,000
New +$6.16M 0.14% 48

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stempoint Capital's ARQT Position: Q1 2026 in Review

Stempoint Capital increased its Arcutis Biotherapeutics (ARQT) stake by 84% in Q1 2026, buying an estimated $4.82M and bringing the position to 413,792 shares worth $9.75M. The position accounts for 1.87% of the portfolio, ranked #15.

Stempoint Capital first reported a position in ARQT in Q4 2023 and has held it in 10 quarters since. The position peaked at $21.9M in Q1 2024. 269 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Stempoint Capital held 413,792 shares of Arcutis Biotherapeutics worth $9.75M as of Q1 2026.
  • Stempoint Capital bought 189,052 Arcutis Biotherapeutics shares in Q1 2026, an estimated $4.82M.
  • Arcutis Biotherapeutics made up 1.87% of Stempoint Capital's portfolio in Q1 2026, its #15 holding.
  • Stempoint Capital first reported a position in Arcutis Biotherapeutics in Q4 2023 and has held it in 10 quarters since.
  • Stempoint Capital's Arcutis Biotherapeutics position peaked at $21.9M in Q1 2024.
  • 269 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.